UroGen Reports Durable JELMYTO Response in Five-Year Follow-Up
UroGen said final results from the Olympus five-year follow-up study reinforce durable response with JELMYTO in patients with low-grade upper tract urothelial cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
UroGen Reports Five-Year Olympus Follow-Up Data on JELMYTO
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce durable response with JELMYTO in patients with low-grade upper tract urothelial cancer.